newsA targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have…
16 June 2022 | By Sarah Wills (European Pharmaceutical Review)
A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have long-term anti-tumour effects in patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs).